Log in

2197 Clover Biopharmaceuticals Ltd. HKEX · China

Clover Biopharmaceuticals (2197) news

Clover Biopharmaceuticals Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2197, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Clover Biopharmaceuticals news

We have not published a story on Clover Biopharmaceuticals yet. When there is news, it will appear here.

Questions about Clover Biopharmaceuticals

What is the ticker symbol of Clover Biopharmaceuticals?

Clover Biopharmaceuticals Ltd. trades under the ticker 2197 on HKEX.

Where is Clover Biopharmaceuticals listed?

Clover Biopharmaceuticals Ltd. is listed on HKEX.

Which country or territory is Clover Biopharmaceuticals listed under?

Our directory records Clover Biopharmaceuticals Ltd. under China.

What does Clover Biopharmaceuticals do?

Our directory classifies Clover Biopharmaceuticals Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Clover Biopharmaceuticals?

The ISIN recorded for Clover Biopharmaceuticals Ltd. is KYG2280A1076.

Does aibio.space cover Clover Biopharmaceuticals?

aibio.space lists Clover Biopharmaceuticals Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Clover Biopharmaceuticals?

Companies in our directory listed in the same country and business area as Clover Biopharmaceuticals: Xiamen Kingdomway Group Co., Kingchem (Liaoning) Life Science Co., Cachet Pharmaceutical Co., Tasly Pharmaceutical Group Co., Zhangzhou Pientzehuang Pharmaceutical Co., Beijing Science Sun Pharmaceutical Co..

Investor discussion: Clover Biopharmaceuticals

Members talk about Clover Biopharmaceuticals (2197). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Clover Biopharmaceuticals, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1). PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES AND/OR SELL OR TRANSFER TREASURY SHARES; (2). PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3). PROPOSED RE-APPOINTMENT OF AUDITOR; (4). PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (5). NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: (1). PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES AND/OR SELL OR TRANSFER TREASURY SHARES; (2). PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3). PROPOSED APPOINTMENT OF AUDITOR; AND (4). NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Clover Biopharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    Voluntary Announcement Clover Announces Positive Australia Phase 2 Clinical Data for RSV + hMPV + PIV3 Respiratory Combination Vaccine Candidates in Older Adults

  2. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  3. HKEXnews

    POSITIVE PROFIT ALERT

  4. HKEXnews

    SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  5. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2026

  6. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT

  7. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  8. HKEXnews

    (1). PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES AND/OR SELL OR TRANSFER TREASURY SHARES; (2). PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3). PROPOSED RE-APPOINTMENT OF AUDITOR; (4). PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (5). NOTICE OF ANNUAL GENERAL MEETING

  9. HKEXnews

    Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form

  10. HKEXnews

    Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form

  11. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO INSIDE INFORMATION

  12. HKEXnews

    Voluntary Announcement Clover Completes Enrollment in Australian Phase 2 Clinical Trial for RSV + hMPV + PIV3 Respiratory Combination Vaccine Candidates

  13. HKEXnews

    GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUs PURSUANT TO THE RSU SCHEME

  14. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES ADDITIONAL POSITIVE U.S. PHASE I CLINICAL DATA FOR RSV RE-VACCINATION IN OLDER ADULTS

  16. HKEXnews

    INSIDE INFORMATION

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT CLOVER INITIATES PHASE 2 CLINICAL TRIAL FOR RSV - HMPV - PIV3 RESPIRATORY COMBINATION VACCINE CANDIDATES

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CLOVER ANNOUNCES POSITIVE PHASE I CLINICAL DATA FOR RSV-HMPV-PIV3 COMBINATION VACCINES AND FOR RSV RE-VACCINATION IN OLDER ADULTS

  19. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

  20. HKEXnews

    Nomination Committee - Terms of Reference

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2197 on TradingView.

Listing details

Clover Biopharmaceuticals Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2197, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Clover Biopharmaceuticals Ltd.
Ticker
2197
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG2280A1076
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.